NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for liver and metabolic diseases.
/10
Transparency ranking
Work at NeuroBo Pharmaceuticals, Inc.?
Tell us what we're missing about working at NeuroBo Pharmaceuticals, Inc. so we can make the job search more transparent for everyone.
Tell us what it's like to work at NeuroBo Pharmaceuticals, Inc.!Description
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for liver and metabolic diseases. Their primary focus is on transforming cardiometabolic diseases with their two lead drug candidates, DA-1241 and DA-1726. DA-1241 is a GPR119 agonist currently in Phase 2a clinical trials for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), while DA-1726 is a dual oxyntomodulin analog agonist for the treatment of obesity, with FDA clearance for a Phase 1 clinical trial expected to begin in the first half of 2024.
NeuroBo is strategically partnered with Dong-A ST Co. Ltd., a leading Korean pharmaceutical company, which provides access to R&D, scientific, and CMC expertise. NeuroBo's approach is based on leveraging their understanding of gut peptides and their role in metabolic regulation to develop innovative treatments that address the unmet needs of patients with liver and metabolic diseases. They are committed to advancing their pipeline of promising therapies to improve patient outcomes and contribute to the advancement of the field.
Mission
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for chronic liver and related metabolic diseases. They are driven by a mission to transform cardiometabolic diseases through innovative drug development, particularly in the areas of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes Mellitus (T2DM), and obesity.
Culture
NeuroBo Pharmaceuticals fosters a collaborative and innovative culture, driven by a shared commitment to advancing novel therapies for liver and metabolic diseases. The company values scientific excellence and a dedication to improving patient outcomes. Their partnerships with global organizations like Dong-A ST Co., Ltd., demonstrate a focus on international collaboration and a commitment to leveraging expertise from diverse backgrounds. The company's emphasis on research and development suggests a culture that embraces exploration, creativity, and a dedication to pushing the boundaries of scientific understanding.
DE&I
NeuroBo Pharmaceuticals, Inc. does not have any publicly available information about their approach to diversity, equity, and inclusion.
Similar companies. But verified.
